|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
T helper 17 (Th17)-cell differentiation triggered by interleukin-6 (IL-6) via STAT3 activation promotes inflammation in inflammatory bowel disease (IBD) patients.
|
30770344 |
2019 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Both PDGF-BB and interleukin 6 (IL-6) showed the strongest correlations with clinical features of IBD.
|
31567972 |
2019 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparing the change of the variables indicated a significant decrease in fecal calprotectin (P < 0.001), Mayo score (P < 0.001), ESR (P < 0.001), INF-γ (P < 0.001), IL-6 (P < 0.001), waist circumference (P = 0.02), Diastolic Blood Pressure (DBP) (P < 0.001), and Systolic Blood Pressure (SBP) (P < 0.001) and a significant increase in TGF-β (P < 0.001) and Inflammatory Bowel Disease Questionnaire-Short form (IBDQ-9) score (P < 0.001) in the GF and FO groups compared to the control.
|
31519285 |
2019 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data define a new function of IL-6 and suggest that caution should be exercised when targeting IL-6 in IBD patients, particularly those with defects in IL-10 signaling.
|
31679013 |
2019 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
It was observed that R. intestinalis supernatant ameliorated IBD colitis by reducing the number of inflammatory macrophages and Th17 cells in the colon, and by downregulating the expression of IL‑6 and STAT3.
|
31173202 |
2019 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of the study was to evaluate bone mineral density (BMD) by densitometry and the concentration of interleukin 6, osteoprotegerin (OPG) and sRANKL protein (sRANKL) by ELISA in patients with IBD in relation to the control group; to assess the relationship between IL-6, OPG, sRANKL and BMD; and to assess the impact of disease duration and number hospitalization on BMD.
|
29558031 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Gastrointestinal perforation may be a specific concern for agents directed at interleukin-6 pathways, and some reports have raised the question of whether interleukin-17 inhibition may elevate inflammatory bowel disease risk.
|
29149926 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting IL-6 may reduce neutrophil-associated extraintestinal manifestations in IBD patients.
|
29684360 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin 6 (IL6) is an inflammatory cytokine; signaling via its receptor (IL6R) is believed to contribute to development of inflammatory bowel diseases (IBD).
|
29775600 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, IL-6 blockers or protein-rich-diet-linked mTORC1 activation may prevent IBD-associated CRC.
|
29275959 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-6 (IL-6) induced intestinal epithelial barrier dysfunction is involved in the pathological process of IBD.
|
29680209 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
As published serum levels of IL-6 and its soluble receptors sIL-6R and sgp130 in IBD are from small cohorts and partly contradictory, we systematically evaluated IL-6, sIL-6R and sgp130 levels as markers of disease activity in Crohn's disease (CD) and ulcerative colitis (UC).
|
29748708 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
cAT-MSC-secreted TSG-6 ameliorated IBD and regulated colonic expression of pro- and anti-inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and interleukin-10.
|
29625582 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The proinflammatory cytokine, interleukin-6 (IL-6), plays a critical role in many chronic inflammatory diseases, particularly inflammatory bowel disease.
|
30200658 |
2018 |
|
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, more recent evidence from various autoimmune diseases (e.g., inflammatory bowel disease, rheumatoid arthritis) has shown that the IL-6 activity is more complex with important effects also on tissue homeostasis, regeneration, and metabolism.
|
28642760 |
2017 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IL-6 and TGFβ1 were overexpressed (RQ>10) in non-inflamed mucosa from IBD patients compared to the normal mucosa from the controls.
|
28088612 |
2017 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study provides a quantitative analysis regarding the Th17/Treg cell balance in peripheral blood of children with IBD and its association with serum IL-6 and IL-23 level.
|
29441874 |
2017 |
|
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of the study was to evaluate associations between inflammatory bowel disease (IBD) presentation and variants in NOD2, TLR4, TNF-α, IL-6, IL-1β, and IL-RN genes in order to identify possible environmental factors that may affect IBD occurrence, investigate potential predictors for surgical treatment of IBD, and correlate the presence of granulomas in biopsy specimens with clinical characteristics of Crohn's disease (CD) patients.
|
28452812 |
2017 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Canonical NF-κB pathway activation is well studied in IBD and is associated with the rapid, acute production of diverse proinflammatory mediators, such as COX-2, IL-1β, and IL-6.
|
27508514 |
2016 |
|
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Meta-analyses showed that polymorphisms in TLR2 (rs3804099, OR (95% CI) = 2.17 (1.35-3.47)], rs11938228 [OR = 0.64 (0.43-0.96)], TLR4 (rs5030728) [OR = 3.18 (1.63-6.21)], TLR9 (rs352139) [OR = 0.43 (0.21-0.88)], TNFRSF1A (rs4149570) [OR = 2.06 (1.02-4.17)], IFNG (rs2430561) [OR = 1.66 (1.05-2.63)], IL6 (rs10499563) [OR = 1.65 (1.04-2.63)] and IL1B (rs4848306) [OR = 1.88 (1.05-3.35)] were significantly associated with response among IBD patients using clinical response criteria.
|
27417569 |
2016 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased IL-6 expression has been reported in IBD patients, which may be associated with intestinal barrier function through discontinuous tight junction (TJ).
|
27980357 |
2016 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
EVs from patients with IBD with a high endoscopic score (≥1) contained significantly higher mRNA and protein levels of interleukin 6 (IL-6), IL-8, IL-10, and tumor necrosis factor α than EVs from healthy controls.
|
27271497 |
2016 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
As the pro-inflammatory cytokine interleukin-6 (IL-6) had been identified as a crucial regulator in the immunopathogenesis of inflammatory bowel diseases, we treated the patient with biweekly intravenous infusions of an anti-IL-6R antibody (tocilizumab) for 12 wk.
|
26668517 |
2015 |
|
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The interleukin-6 (IL-6)/STAT3 signaling regulates survival and proliferation of intestinal epithelial cells and plays an important role in the pathogenesis of inflammatory bowel disease and colorectal cancer.
|
24651526 |
2014 |
|
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The presence of IBD, but not the genetic risk load, was correlated to differential mRNA expression for IL6 in unstimulated peripheral blood mononuclear cells and to IL23A and RORC in response to stimulation.
|
24662057 |
2014 |